Safety evaluation
ADVERSE REACTIONS, POSTOPERATIVE BLEEDING
The incidence of defects derived from TDM-621 treatment and AE (including abnormalities in clinical test values, postoperative bleeding for 7 and 28 days after ESD, and adverse reactions) were assessed for the evaluation of safety.